1
/
of
1
Elabscience
SKU:PKSH033925
Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc)
Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc)
Regular price
$200.00 USD
Regular price
Sale price
$200.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc), a cutting-edge product designed to revolutionize the field of immunology. This meticulously engineered receptor offers a novel approach to understanding and manipulating immune responses, paving the way for groundbreaking advancements in therapeutic interventions.
Crafted with utmost precision, the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc) boasts a fusion protein structure that combines the functional domains of LAIR1 with the constant region of a mouse IgG1 Fc fragment. This fusion enables enhanced stability, prolonged half-life, and improved binding affinity, ensuring optimal performance in a variety of experimental settings.
The Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc) exhibits exceptional versatility, facilitating comprehensive investigations into the intricate mechanisms underlying immune regulation. Its ability to interact with various ligands, including collagen and soluble LAIR1 ligands, empowers researchers to delve into the complexities of immune cell signaling pathways, receptor-ligand interactions, and downstream cellular responses.
This groundbreaking product holds immense potential for therapeutic applications. By leveraging the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc), researchers can explore novel avenues for immunomodulation, immune checkpoint blockade, and targeted immunotherapies. Its unique attributes, such as its ability to modulate immune cell activation and inhibit immune responses, make it an invaluable tool in the pursuit of innovative therapeutic strategies.
In addition to its scientific prowess, the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc) is manufactured under stringent quality control measures, ensuring consistent and reliable results. Each batch undergoes rigorous testing to guarantee purity, stability, and functionality, instilling confidence in researchers and clinicians alike.
In summary, the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc) represents a groundbreaking advancement in the field of immunology. With its unrivaled capabilities, this meticulously engineered receptor opens up new frontiers in immune regulation research and therapeutic development. Embrace the future of immunology with the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc)
Crafted with utmost precision, the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc) boasts a fusion protein structure that combines the functional domains of LAIR1 with the constant region of a mouse IgG1 Fc fragment. This fusion enables enhanced stability, prolonged half-life, and improved binding affinity, ensuring optimal performance in a variety of experimental settings.
The Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc) exhibits exceptional versatility, facilitating comprehensive investigations into the intricate mechanisms underlying immune regulation. Its ability to interact with various ligands, including collagen and soluble LAIR1 ligands, empowers researchers to delve into the complexities of immune cell signaling pathways, receptor-ligand interactions, and downstream cellular responses.
This groundbreaking product holds immense potential for therapeutic applications. By leveraging the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc), researchers can explore novel avenues for immunomodulation, immune checkpoint blockade, and targeted immunotherapies. Its unique attributes, such as its ability to modulate immune cell activation and inhibit immune responses, make it an invaluable tool in the pursuit of innovative therapeutic strategies.
In addition to its scientific prowess, the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc) is manufactured under stringent quality control measures, ensuring consistent and reliable results. Each batch undergoes rigorous testing to guarantee purity, stability, and functionality, instilling confidence in researchers and clinicians alike.
In summary, the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc) represents a groundbreaking advancement in the field of immunology. With its unrivaled capabilities, this meticulously engineered receptor opens up new frontiers in immune regulation research and therapeutic development. Embrace the future of immunology with the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 1/LAIR1/CD305 (C-mFc)
Share
